IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether IBD drug Entyvio (vedolizumab) from Takeda Pharma (TYO: 4502), Japan's largest drug maker, offers additional benefits over standard therapies. The conclusion reached by the IQWiG was that the therapeutic benefits of the drug in this setting have not been proven in light of the current data. Crohn's disease and ulcerative colitis are the principal types of chronic inflammatory bowel disease that affect the colon and the small intestine. Entyvio (vedolizumab) is a treatment option when conventional therapies or the use of tumor
Subscribe or to access all post and page content.